Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Hepatitis C virus (HCV) infection is one of the commonest causes of liver cirrhosis and hepatocellular carcinoma. This review deals with treatment of chronic HCV infection with a combination of interferon and ribavirin. Recent trials have shown that approximately 40% of patients will clear HCV with combination treatment. This is an important advance in the treatment of this serious viral infection.


Journal article


Hosp Med

Publication Date





357 - 361


Antiviral Agents, Carcinoma, Hepatocellular, Drug Therapy, Combination, Hepatitis C, Chronic, Humans, Interferon-alpha, Liver Cirrhosis, Liver Neoplasms, Recombinant Proteins, Recurrence, Ribavirin